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Abstract
Duchenne muscular dystrophy (DMD) is a lethal, X-linked muscle-wasting disease caused by lack of the cytoskeletal protein
dystrophin. There is currently no cure for DMD although various promising approaches are progressing through human clinical
trials. By pharmacologically modulating the expression of the dystrophin-related protein utrophin, we have previously
demonstrated in dystrophin-deficient mdx studies, daily SMT C1100 treatment significantly reduced muscle degeneration
leading to improved muscle function. This manuscript describes the significant disease modifying benefits associated with
daily dosing of SMT022357, a second-generation compound in this drug serieswith improved physicochemical properties and a
more robust metabolism profile. These studies in the mdxmouse demonstrate that oral administration of SMT022357 leads to
increased utrophin expression in skeletal, respiratory and cardiacmuscles. Significantly, utrophin expression is localized along
the length of the muscle fibre, not just at the synapse, and is fibre-type independent, suggesting that drug treatment is
modulating utrophin transcription in extra-synaptic myonuclei. This results in improved sarcolemmal stability and prevents
dystrophic pathology through a significant reduction of regeneration, necrosis and fibrosis. All these improvements combine to
protect themdxmuscle from contraction induced damage and enhance physiological function. This detailed evaluation of the
SMT C1100 drug series strongly endorses the therapeutic potential of utrophin modulation as a disease modifying therapeutic
strategy for all DMD patients irrespective of their dystrophin mutation.
Introduction
Duchenne muscular dystrophy (DMD) is an X-linked recessive
disorder caused by genetic mutation in the dystrophin gene
and characterized by progressive muscle wasting and weakness
(1). This disorder affects 1 in 3500 boys and de novo mutations
continue to arise in all populations worldwide (2). Males who
carry the dystrophin mutations display normal development
until 3–5 years of age, after which the first signs of DMDmanifest
as abnormal gait, weakness in proximal muscles and calf muscle
pseudo hypertrophy. These symptoms progress relentlessly and
patients usually requirewheelchair support by the age of 12 years
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(3,4) and succumb to heart or respiratory failure by 30 years of
age (5).
Dystrophin is essential to maintain the biomechanical prop-
erties of fibre strength, flexibility and stability in skeletal muscle.
It forms part of the dystrophin-associated protein complex
(DAPC) which comprises many other proteins including dystro-
glycans, sarcoglycans, α-dystrobrevin, syntrophins and sarco-
span. This complex assembles at the sarcolemma to form a
stable link between the extracellular matrix and actin cytoskel-
eton allowing myofibres to cope with repeated cycles of muscle
contraction and relaxation (6). DMD patients experience repeated
cycles of muscle necrosis and regeneration leading to eventual
replacement of muscle fibres by adipose and connective tissue
(7). The urgency to seek a cure for DMDhas resulted in parallel ef-
forts to develop exon skipping (8,9), termination codon read
through (10), dystrophin gene replacement or editing therapies
(11,12) and development of non-dystrophin strategies (13–15).
Each strategy has its potential caveats and may not benefit all
DMD patients.
Utrophin is a structural and functional autosomal paralogue
of dystrophin (16) that is ubiquitously localized at the sarco-
lemma in utero and is progressively replaced by dystrophin
(17–19). In adults, the utrophin A isoform is enriched at the
neuromuscular and myotendinous junctions of skeletal muscle
(20) as well as the sarcolemma of regenerated myofibres (21). In
DMD patients and the mdx mouse model, utrophin is naturally
increased in regions of the fibres undergoing repair due to the
absence of dystrophin (21,22). Studies with a transgenic mdx
mouse expressing utrophin under the control of the HSA pro-
moter (Fiona mice) have shown that in muscle, a 3–4 fold increase
in wild-type utrophin protein levels successfully prevents the
dystrophic pathology (23,24). Importantly, this utrophin protein
increase is significantly less than the normal utrophin protein
levels in kidney and liver (23). Deliberately over expressing utro-
phin protein showed no detrimental effect in a broad range of
murine tissues (25).
Despite its functional similarities to dystrophin, utrophin ex-
hibits different modes of interaction with actin (26) and microtu-
bules, and may not prevent microtubule lattice derangement
(27). It is important to note that the muscle function is fully re-
stored in the Fiona mice (28), suggesting that microtubule ar-
rangement is likely to be part of a more complex mechanism of
contraction-induced injury in the mdx mouse and probably not
the sole contributing factor involved in this phenomenon. Unlike
dystrophin, utrophin is unable to restore nNOS localization (29).
However, a recent study reported no relationship between the ex-
pression of nNOS at the sarcolemma and the disease severity in
Becker patients (30) as many BMD patients lacking the nNOS
binding site in dystrophin remain mildly affected and ambulant.
The constitutively expressing utrophin mdx mouse showed sig-
nificant improvement without nNOS membrane localization,
suggesting that there may be compensatory nNOS pathways
(29,31). Despite these subtle differences between utrophin and
dystrophin, a small increase in utrophin levels delays the age of
wheelchair support in patients (32) and utrophin can act as an ef-
fective surrogate for dystrophin in mdx muscles (24,33,34).
The significant advantage of utrophin modulation therapy
and the continual expression of utrophin in muscle and heart
is that the approach is applicable to all DMD patients regardless
of the dystrophinmutation. Furthermore, a systemic strategy de-
signed to increase the endogenous utrophin level to treat all skel-
etal muscle (including the diaphragm) and heart, would not be
anticipated to result in an immune response (25). To date, direct
delivery of the protein (35) or stabilization of the protein or RNA
(36,37), viral approaches (38,39), non-viral strategies such as
recombinant biglycan (40) and oral compound administration
designed to modulate the utrophin expression at the transcrip-
tional level (41,42), showed thatmaintaining utrophin expression
in mdx muscle fibres could decrease the progression of the dis-
ease and represents a promising therapeutic avenue for DMD.
SMTC1100was the first new chemical entity (NCE) specifically
designed to target the utrophin-A promoter (43) which has pro-
gressed into clinical development. Mdx mice showed marked
improvement in functional calcium-dependent parameters, de-
creased serum creatine kinase levels, muscle fibrosis, necrosis
and membrane damage in skeletal muscle following eccentric
contractions (41). SMT C1100 was deemed safe and well tolerated
in a Phase 1a healthy volunteer study, althoughwith a lower than
expected drug exposure level (15) and successfully completed a
Phase 1b study in DMD boys.
In this study, we evaluated in greater depth another com-
pound, SMT022357, from the SMT C1100 family, for its effects
on several skeletal muscle groups, including the diaphragm,
and heart. SMT022357 is a second-generation compound struc-
turally related to SMT C1100 with improved physicochemical
properties and amore robustmetabolismprofile. This compound
showed effective up-regulation of utrophin in all muscle groups
and significant improvement in the overall muscle pathophysi-
ology of themdxmouse. These results further cement the ration-
ale of developing novel NCEs capable of modulating utrophin
transcription as a potential therapy for all DMD patients.
Results
In vitro upregulation of utrophin
To study the ability of SMT022357 to increase the transcription of
the endogenousmouse utrophin gene (Utrn), we used the screen-
ing line H2K-mdx utrnA-luc (41). These murine myoblast cells
contain a stably integrated 8.4 kb of the human utrophin pro-
moter linked to a luciferase reporter gene. This region of the utro-
phin promoter includes all the motifs known to control utrophin
expression as previously described (44).
SMT022357 shows a maximal increase of 3-fold in luciferase
compared with vehicle (Fig. 1A). No stabilization or inhibition of
the luciferase activity was noted (data not shown). Furthermore,
no change in proliferation was observed after a treatment with
SMT022357 (Supplementary Material, Fig. S1). In vitro dosing of
murine myoblasts with 3 µ of SMT022357 led to a 50% increase
in utrophin mRNA when compared with vehicle after 2 days of
treatment (Fig. 1B). Treatment of murine DMD cells with
SMT022357 showed a 2.5-fold increase in utrophin protein level
at an optimal concentration of 10 µ after 3 days of treatment
(Fig. 1C). In comparison, SMT C1100 led to a 30% increase in
UtrnmRNA level and resulted in a 2.0-fold increase in UTRN pro-
tein level (41). These data demonstrate the in vitro potential of
SMT022357 to increase the level of utrophin expression.
In vivo upregulation of utrophin
To investigate the in vivo activity of SMT022357, 2-week-old mdx
mice were orally dosed daily with 30 mg/kg of SMT022357 or ve-
hicle for 5 weeks. Immunofluorescence using a utrophin anti-
body revealed a qualitative increase in sarcolemma-bound
utrophin in the transverse of EDL and SOL muscles (Fig. 2A). In
the mdx mouse, utrophin localization is fragmented and dis-
continuous along the myofibre highlighting the regions within
the fibre where regeneration is taking place in order to repair
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the damaged membrane (Fig. 2A–C). After treatment with
SMT022357, utrophinwas continuously localized along the entire
length of the sarcolemma in longitudinal tibialis anterior (TA)
sections suggesting that drug treatment is modulating utrophin
transcription in myonuclei along the length of the fibre (Fig. 2B).
The integrity of the membranes was confirmed with desmin im-
munostaining (Fig. 2B). Co-localizationwith α-bungarotoxin anti-
body in TAmuscles confirmed, despite a preferred accumulation
at the neuromuscular junction, a qualitative increase of utrophin
at extra-synaptic regions of the sarcolemma (Fig. 2C). Western
blot analysis and quantification in EDL and SOLmuscles demon-
strated a 1.8- and 1.9-fold increase, respectively, of the utrophin
protein levels after treatment with SMT022357 (Supplementary
Material, Fig. S2A).
Utrophin is up-regulated during regeneration in skeletalmus-
cle (21). In order to study regeneration after treatment with
SMT022357, the expression of different regeneration/myogenic
differentiation markers (45) was analysed by semi-quantitative
RT–PCR. A decrease in all these markers was noted in EDL mus-
cles treated with SMT022357 (Fig. 3A), demonstrating that daily
drug treatment for 5 weeks results in a reduction in regeneration
and, importantly, that the increase of utrophin is independent of
this process. This suggests that the higher levels of utrophin
must be derived from drug treatment rather than regeneration.
It is alsowell established that dystrophicmuscle type I fibres pre-
sent greater utrophin expression than type II fibres (36,46,47).
Thus, we investigated the expression of type I, IIa and IIb myosin
heavy chains in EDLmuscle. No change infibre-type composition
was noted after treatment with SMT022357 (Fig. 3B), supporting
the fact that SMT022357 increases the utrophin expression in
both fast-twitch (type II) and slow-twitch (type I) fibres.
Taken together, our results demonstrated that daily oral treat-
ment with SMT022357 for 5 weeks in the mdx mouse resulted in
increased levels of utrophin throughout the dystrophicmyofibres
and extrasynaptic domains, independently of regeneration or
change in fibre-type composition.
SMT022357 ameliorates the pathology
in skeletal muscle
The mdx mouse exhibits a mild form of muscular dystrophy
with elevated serum levels of creatine kinase (48) and histo-
logical changes consistent with myofibre damage (49). Treat-
ment with SMT022357 results in a 47% decrease of serum CK
levels (Fig. 5A), demonstrating that the increased levels of utro-
phin derived from drug treatment is reducing the amount of
membrane damage reducing the rate of CK leaking into general
circulation.
Figure 1. In vitro activity of SMT022357. (A) SMT022357 in vitro dose response inmurineH2k-mdx utrnA-luc cells expressing the human utrophin promoter linked to afirefly
luciferase reporter gene. Cells were treated with compound for 24 h in standard growth medium containing 1% DMSO. The chart shows relative luminescence (RLU) in
relation to five different doses (0.1, 0.3, 1, 3 and 10 µM) of SMT022357. (B) SMT022357 significantly increased mRNA copy number of the utrophin transcript in murine
myoblast cells. Cells were exposed to different dose of SMT022357 in standard media with 0.1% DMSO (vehicle) for 24 hours with six biological replicates. Utrophin
transcripts were normalised with 18s and b2m. Values are mean ± SEM of n = 6 per condition; *P < 0.05, **P < 0.01, ***P < 0.001. (C) Relative utrophin protein expression in
murine cells treated with SMT022357 was determined by western blot and standardized for α-actinin loading. Western blots showing 2.5-fold increase of utrophin
protein expression with 10 µM of SMT022357 when compared with vehicle. Relative utrophin expression is shown as mean ± SEM of n = 3 per condition.
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Next, we evaluated the restoration of membrane stability
in dystrophin-negative myofibres following the increased level
of utrophin at the sarcolemma. Key elements of the DAPC com-
plex such as β-dystroglycan, which directly binds to laminin
in the extracellular matrix, are not properly localized into the
sarcolemma in DMD patients resulting in muscle damage after
repeated contractions (50). As illustrated in Figure 4, in EDL mus-
cles treated with SMT022357, localization of β-dystroglycan and
dystrobrevin (another member of the DAPC) was restored to the
sarcolemma of all fibres. This translated to a 1.7- and 1.3-fold
increase of β-dystroglycan and dystrobrevin expression, respect-
ively, when quantified bywestern blots (SupplementaryMaterial,
Fig. S2B). This data predicts an improvement of muscle mem-
brane stability when utrophin acts as a dystrophin surrogate to
maintain the DAPC complex including the major component of
the DAPC-laminin axis.
Improved muscle pathology of SMT022357 treated mdx mice
compared with vehicle was observed in SOL (type I) and EDL
(type IIb) muscles (Fig. 5B). A biomarker of fibre regeneration,
the number of centrally nucleated fibres, fell significantly in
EDL (−20.1%, P = 0.03, Fig. 5C) and SOL (−19.6%, P = 0.02; Fig. 5E) re-
sulting in a reduction of the necrotic areas in EDL (−63.1%, P =
0.02, Fig. 5D) and SOL (−57.3%, P = 0.06. Fig. 5F). This clearly de-
monstrates a significant reduction in pathology and regener-
ation in these muscles. The 2-week-old mdx mice present a
18.3% of centronucleation (SEM = 0.01; TA, n = 3) and a 4.25%
(SEM = 1.96; TA, n = 3) of necrosis compared with wild-type
mouse. Therefore, SMT022357 treatment not only prevents the
dystrophic pathology but may also ameliorate some parameters
of the mdx phenotype.
Furthermore, we investigated if the increased membrane
stability and reduction in pathology achieved by SMT022357
treatment translated into functional improvements in muscle.
Ex vivo analysis of EDL muscles after 5 weeks of daily SMT022357
treatment demonstrated that after five eccentric contractions,
SMT022357 results in a 50% (P = 0.004) decrease in force drop com-
pared with vehicle-treated mdxmice (Fig. 6). No changes were ob-
served in muscle mass, absolute or specific force when treated
with SMT022357 in comparison to the vehicle (data not shown).
In summary, these data showed that daily SMT022357 treat-
ment for 5 weeks results in increased localization of utrophin
along the fibre membrane. In turn, this addresses the primary
cause of fibre degeneration with the direct consequence of
increased sarcolemma stability in hind-limb muscles of the
mdx mouse, leading to favourable endpoints such as reduced
regeneration and necrosis, and enhanced protection of the
muscle against damage. Starting drug treatment at 2 weeks of
age significantly ameliorates the pathology in themdxmice.More-
over, similar benefits obtained in EDL and SOL muscle indicate
that SMT022357 acts independently of the fibre-type composition,
the muscle structure and the basal level of endogenous utrophin.
Benefits of SMT022357 treatment in diaphragmandheart
In relation toDMD, it is of significant importance to confirm that the
proposed therapy can reduce the dystrophin deficient defects in the
Figure 2. SMT022357 increases utrophin expression in skeletalmuscles. (A) Immunofluoresence staining for utrophin in EDL and SOLmuscles of 7weeks oldmdxmice treated
for 5 weeks with 30mg/kg/day SMT022357 or vehicle. Transverse sections were stained with anti-utrophin polyclonal antibody URD40 and anti-rabbit secondary antibody.
Scale bar: 100 µm. (B) Longitudinal cryosections of TA muscle following treatment of mdx mice homogenously increased the utrophin expression along the myofiber after
treatment with SMT022357 compared to vehicle group. Scale bar: 100 µm. (C) Co-immunohistochemical staining of TA muscle with utrophin, α-Bungarotoxin and DAPI
prepared frommdxmice treated with SMT022357. White arrows indicate utrophin expression in extra-synaptic regions of the sarcolemma. Scale bar: 50 µm.
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diaphragm, the major respiratory muscle. Unlike skeletal and car-
diac muscles, themdx diaphragm closely mimics the degeneration
observed in DMD patients (51–53) which suggests that the early
dystrophic changes are most prominent in this muscle. In the mdx
mouse, thediaphragmexhibits ahighly dystrophic pathologyand is
the most reliable indicator of damage or recovery (54,55).
Figure 4. SMT022357 treatment improves fibre membrane stability. Immunofluoresence staining for β-dystroglycan, and dystrobrevin in EDL muscle of 7 weeks old mdx
mice treated for 5 weeks with 30 mg/kg/day SMT022357 or vehicle shows that key components of the DAPC complex are properly localised to the sarcolemma after
SMT022357 treatment. n = 3 per group; Scale bar: 100 µm.
Figure 3. SMT022357 treatment results in a decrease in regeneration with no change in fibre type composition in the skeletal muscle. (A) Semi-quantitative RT-PCR
demonstrates a decrease of skeletal muscle regeneration/myogenic differentiation markers Bex1, myogenin and cell cycle dependent-kinase inhibitors (CDKI) p21 and
p27 from EDL of mdx mice dosed with SMT022357 (357, n = 8) compared to vehicle (Ve, n = 8). S13 ribosomal protein was used as an internal control for the RT-PCR. A
12% decrease in Bex1 (P = 0.034), 21% decrease in p21 (P = 0.002), 67% decrease in p27 (P < 0.001) and 64% decrease in Myogenin (P < 0.001) transcript levels were
quantified by ImageJ software in SMT022357 group compared to vehicle. (B) Immunofluoresence staining for type 1a, 2a and 2b fibre types in the EDL of 7 weeks old
mdxmice treated for 5 weeks with 30 mg/kg/day SMT022357 or vehicle (n = 6 per group). Sections were stained with anti-MYHC1, anti-MYHC2A anti-MYHC2B and anti-
mouse secondary antibody. Percentage of type 1a, 2a and 2b fibre types was quantified by ImageJ software in the whole EDL muscle (n = 6 per group). No change was
observed in fibre type composition of whole EDL muscle treated with SMT022357 compared to treatment with vehicle only. Scale bar: 100 µm.
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The expression of utrophin was analysed by immunofluore-
sence and western blot. After treatment with SMT022357,
utrophin staining appeared more homogeneous around the dia-
phragm fibre membranes compared with vehicle-treated mice
(Fig. 7A). Western blot analysis showed that after 5 weeks of
SMT022357 treatment total levels of utrophin protein were in-
creased by 20% in the mdx mouse diaphragm (Supplementary
Material, Fig. S2A). Analysis of the diaphragm pathology after
SMT022357 treatment demonstrated a significant decrease of
centrally nucleated fibres by 35.9% (P < 0.0001), a biomarker of
regeneration, and a 56.6% (P = 0.04) reduction of necrotic area
compared with vehicle treated (Fig. 7B and C).
In DMD muscles, endomysial fibrosis is a hallmark feature of
the pathology. Although themdxmouse does not recapitulate the
fibrotic progression observed in patients, themdx diaphragm de-
monstrates early dystrophic lesions including fibrosis at an early
age (56). The mechanisms by which fibrosis develops in DMD pa-
tients remain largely unknown but the elevated expression of
various inflammatory cytokines, such as transforming growth
factor-β1 (TGF-β1), and tumour necrosis factor (TNF) stimulate
an excessive amount of extracellular matrix proteins which
could lead to fibrosis. Previous studies described significantly
higher type-1 collagen content, TGF-β1 and MMP-2/9 mRNA
levels, and signs of fibrosis in 6-week-old mdx mice compared
with wild-type littermates (57,58). Thus, we chose to investigate
the potential benefits on fibrosis development in the diaphragm
ofmdxmice treated for 5 weeks with SMT022357. Compared with
mice treated with the vehicle, qualitative Trichrome Masson
staining is reduced (Fig. 7A) and quantification revealed that
SMT022357 resulted in a 15% decrease of fibrosis (Vehicle: fibrotic
Figure 5. SMT022357 prevents muscular dystrophy in skeletal muscle. (A) Creatine kinase (CK) levels in serum following daily oral gavage of mdxmice with 30 mg/kg of
SMT022357 or vehicle from two weeks of age for five weeks. A 47% decrease in serum CK was observed after treatment with SMT022357 compared to vehicle-treated
animals (n = 7-9 per group). (B) H&E-stained transverse muscle sections of EDL muscle (7 weeks of age) in untreated vs. treated mdx mice (n = 10 per group) showing
necrotic areas (black stars) and regenerating fibres (black arrows). Scale bar: 100 µm. (C) Muscle from mice dosed with SMT022357 showed a significant 20.1% (P = 0.03)
decrease in centrally nucleated fibres compared to the vehicle group in EDL muscles. Values are mean ± SEM of n = 9 per groups; *P < 0.05. (D) The necrotic muscle area
in EDL of mice treated with SMT022357 significantly decreased by 63.1% (P = 0.02) compared to the vehicle group. Values are mean ± SEM of n = 9 per groups; *P < 0.05.
(E) Muscle from mice dosed with SMT022357 showed a significant 19.6% (P = 0.02) decrease in centrally nucleated fibres compared to the vehicle group in SOL muscles.
Values are mean ± SEM of n = 7 per groups; *P < 0.05. (F) The necrotic muscle area in SOL of mice treated with SMT022357 decreased by 57.3% (P = 0.06) compared to the
vehicle group. Values are mean ± SEM of n = 7 per groups.
Figure 6. SMT022357 protects the muscle against damage and improves the
muscle function. The difference in force produced between the first and fifth
stretch is represented as a sensitive indicator of the resistance of the muscle to
stretch-induced damage. EDL muscles were stretched at 15% of their fibre
length whilst contracting tetanically. Values are mean ± SEM of n = 10 per group;
**P < 0.01, ***P < 0.001.
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area = 6.8%, SEM = 1.03, n = 7; SMT022357: fibrotic area = 5.8%,
SEM= 0.73, n = 8). Further confirmation of reduced fibrosis is seen
in Figure 7A, where collagen I content is decreased in SMT022357
group.
In DMD, the lack of dystrophin leads to decreased sarcolem-
mal integrity resulting in an increase of cell membrane perme-
ability leading to increased intracellular calcium. Abnormal
levels of intracellular calcium leads to disruption of normal con-
tractile signalling and activates the natural fibre repair process
leading to aberrant degeneration of fibres. Of particular interest,
SMT022357 treatment completely prevented the accumulation of
calcium-rich deposits as depicted by Alizarin Red staining
(Fig. 7D) further demonstrating the significant decrease in mem-
brane damage. These results are in agreement with previous and
recent work (24,59).
Cardiomyopathy is a major cause of death in boys with DMD
(60). Preventing pathology in the heart, a muscle notoriously
difficult to reach, is crucial as the benefits could lead to a sig-
nificant improvement in patient survival. Western blots demon-
strated a 50% increase of the utrophin protein level in the heart
after 5weeks of daily treatmentwith SMT022357 (Supplementary
Material, Fig. S2). This increase in utrophin was wide spread
throughout the heart and localized to cardiomyocyte mem-
branes (Fig. 8). Nevertheless, analysis of 2-month-old mdx
mouse hearts did show 1–2% fibrosis in themid-ventricle regions
and an initial increase in myocardial wall strain and torsion
(61). Older 9–10-month-old mdx mice present distinct signs of
cardiomyopathy (61,62). Further studies are on-going to deter-
mine the benefits of SMT022357 in the mdx heart.
Discussion
This manuscript describes the in vitro and in vivo activity of a se-
cond-generation orally bioavailable small molecule utrophin
modulator compound which targets the utrophin-A promoter.
Dosing of myoblasts with SMT022357 has a similar potency to
the first generation utrophin modulator SMT C1100 (41). The de-
velopment of the second-generation utrophin modulators origi-
nated from a medicinal chemistry program to improve the
physicochemical andmetabolic properties of SMT C1100, follow-
ing observations in the Phase 1 healthy volunteer trial of lower
than expected exposure levels and significant SMT C1100 parent
metabolism (15). SMT022357 has a more robust metabolism pro-
file. Subsequently, the next step in the development of this se-
cond-generation molecule was to assess in vivo efficacy in the
dystrophin deficient mdx mouse.
The daily oral dosing of SMT022357 in the mdx mouse led to
increased utrophin expression in all skeletal muscles tested, dia-
phragm and heart, demonstrating systemic utrophinmodulation
and the efficient distribution of this compound. By pharmaco-
logically modulating the expression of utrophin, SMT022357 ad-
dresses the primary cause of fibre degeneration by protecting the
sarcolemma which includes maintenance of the dystrophin as-
sociated protein complex as exemplified by β-dystroglycan and
Figure 7. SMT022357 improves the pathology in the diaphragm. (A) Immunofluoresence staining for utrophin in the diaphragmof 7weeks oldmdxmice treated for 5weeks
with 30 mg/kg/day SMT022357 or vehicle (n = 10 per group). Sectionswere stainedwith anti-utrophin polyclonal antibodyURD40 and anti-rabbit secondaryantibody. H&E-
stained transverse muscle sections of diaphragm muscle (7 weeks of age) showed improved morphology in treated vs. vehicle mdx mice (n = 10 per group). Masson’s
trichrome staining of diaphragm in untreated vs. treated mdx mice (n = 8) indicated that SMT022357 treatment reduced the amount of collagen infiltration (stained in
blue); immunofluorescence using anti-collagen type I antibody confirmed a decrease of collagen in the muscular endomysium of SMT022357 treated diaphragm. Scale
bar 100 µm. (B) Diaphragms of mice dosed with SMT022357 showed a significant 35.9% decrease in centrally nucleated fibres compared to the vehicle group. Values are
mean ± SEM of n = 8 per groups; ***P < 0.001. (C) The necrotic diaphragm area of mice treated with SMT022357 significantly decreased by 56.6% compared to the vehicle
group. Values are mean ± SEM of n = 8 per group; *P < 0.05. (D) The vehicle mdx diaphragm exhibits positive staining with Alizarin Red indicating the presence of
calcium deposits. SMT022357 treatment completely prevented the calcification. (n = 10 per group); Scale bar: 100 µm.
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dystrobrevin localization at the muscle membrane. This im-
provement in membrane stability leads to a significant decrease
in centrally nucleated fibres (a biomarker of regeneration) and
necrosis in skeletal muscles, resulting in marked functional
improvement as demonstrated by the increased resistance to
damage by eccentric contractions. After 5 weeks of daily oral
treatment with SMT022357, utrophin is localized along the entire
length of the sarcolemma. This first documented evidence of utro-
phin homogeneously localized along the length of 7-week-oldmdx
muscle fibres demonstrates that SMT022357 is capable of inducing
and/or maintaining utrophin transcription from extrasynaptic
myonuclei. The positive modulation of utrophin expression ob-
servedappears tobe independent of any regenerationmechanism.
Biochemical data demonstrating significant reduction in biomar-
kers of regeneration/myogenic differentiation, linked to significant
reduction centrally nucleated fibres, confirmed reduced fibre re-
generation after treatment with SMT022357. Therefore, the obser-
vation of increasing utrophin levels inmuscle after drug treatment
comparedwith the vehicle; plus the reduction in regeneration (the
major source of utrophinproduction) suggests that dosing over the
5-week period results in significantly more fibres expressing utro-
phin comparedwithmdx. Furthermore, SMT022357 did not change
the fibre-type composition in skeletal muscle, confirming that the
modulation of the utrophin expression was independent from
changes in muscle structure. Together, these data demonstrate
that the increased levels of utrophin seen in skeletal and dia-
phragm muscle compared with vehicle-treated mdx mice occurs
directly as a result of the treatment with SMT022357.
Interestingly, SMT022357 treatment resulted in similar in-
creases of utrophin protein level and similar benefits in decrease
of regeneration and necrosis in fibre-type I (1.9×) and fibre-type
IIb (1.8×) skeletal muscles. This observation suggests that modu-
lation of utrophin after treatment with SMT022357 is independ-
ent of the muscle structure known to influence the utrophin
expression in the mdx mouse (47). In addition, it also suggests
that SMT022357 modulates the utrophin levels by a different
mechanism of action compared with AICAR, a small compound
which activates PGC-1α and PPARβ/δ via AMP-activated protein
kinase (AMPK), a nexus of skeletal muscle plasticity (63,64).
These results support the concept that developing a multi-
targeting strategy to utrophin modulation could be considered
in the future.
Importantly, our results demonstrate that the oral delivery of
SMT022357 distributes drug not only to skeletal muscle, but also
to the diaphragm and the heart. As most DMD patients succumb
to respiratory or heart failure (5,60), the potential to stabilize the
disease in these organs could have additional major benefits to
this treatment paradigm for DMD. After daily treatment with
SMT022357 for 5 weeks, the increased level of utrophin coincides
with the significantly reduced pathology of diaphragm muscle
highlighted by various endpoints such as decreased regener-
ation, necrosis, fibrosis and calcium overload. Furthermore, in
the Fiona mice, where utrophin is overexpressed in the skeletal
muscle and the diaphragm, but only modestly in the heart,
cardiac function, specifically ventricular ejection fraction, were
restored to wild-type levels. Thus, ameliorating the pathology
in the diaphragm muscle prevents part of the cardiac defects
observed in the mdx mouse (65).
In muscular dystrophy, the intracellular calcium concentra-
tion is increased (66) and the excitation–contraction coupling
and overall Ca2+ handling is impaired (67,68). Unregulated
calcium influx initiates the disease pathology in dystrophin-
deficientmyofibres and is sufficient to cause a dystrophic pheno-
type in skeletal muscle independent of membrane fragility (69).
Recent studies suggest that utrophin organizes local membrane
microdomains containing mechanosensitive channels and
that the loss of utrophin results in an increased Ca2+ entry (59)
and previously described as one of the first defects corrected
Figure 8. SMT022357 increases utrophin expression in the mdx heart. (A) H&E staining of transverse heart sections in 7-week-old, vehicle- and SMT022357-treated mdx
mice. n = 10 per group. Scale bar: 100 µm. (B) Immunostaining showed an increase of utrophin in the heart of 7-week-old mdx mice after SMT022357 (30 mg/kg/day)
treatment compared to the vehicle group. (n = 10 per group); Scale bar: 100 µm.
Human Molecular Genetics, 2015, Vol. 24, No. 15 | 4219
following constitutive utrophin expression (24). In addition to the
recognized benefits inmaintainingmembrane structural integrity,
utrophin may also positively act on the calcium homeostasis and
further improve the excitation–contraction coupling mechanism.
The complete prevention of the accumulation of calcium deposits
after SMT022357 treatment further supports this theory, demon-
strating the effectiveness of the utrophin transcriptionmodulation
based strategy to correct defects at an early stage of the disease.
In the mdx heart, SMT022357 increased the utrophin expres-
sion by 50%, confirming drug delivery to cardiac muscle. Two-
month-old mdx mouse hearts do show evidence of cardiac
lesions; first signs of fibrosis and an initial increase inmyocardial
wall strain and torsion (61) but only oldermdxmice show distinct
signs of cardiomyopathy (62). Further studies in older or young
exercised mice (70) are needed to determine the benefits of
SMT022357 treatment in the mdx heart. A recent publication de-
monstrated that increasing utrophin expression via an alterna-
tive pharmacological approach protects the mdx mice against
cardiomyopathy (71).
Taken together, these data demonstrate that daily dosing with
a second-generationutrophinmodulator, SMT022357, ameliorates
the dystrophic pathology in themdxmouse. These results confirm
the hypothesis that reduced fibre damage in hind-limb muscle
due to an increase inutrophin levels leads to reduced regeneration
and necrosis, thereby reducing muscle damage. Nevertheless, 5
weeks of treatment with SMT022357 did not normalize all the
parameters studied in 7-week-old mdx mouse. As previously ob-
served with the Fergie mouse, a transgenic mdx mouse with a
mild expression of the utrophin, a 1.3/1.4-fold increase of the utro-
phin protein is not sufficient to obtain a complete rescue of the
mdx phenotype (23). In future, the potential complementarity of
utrophin modulation strategies with other disease stabilizing ap-
proaches such as glucocorticosteroid analogues like VBP-15 (72) or
phosphodiesterase type 5 inhibitors (13) should also be explored.
We have previously reported the synergistic action of SMTC1100
and prednisone (41). The significant benefit of utrophin modula-
tion with daily oral treatment SMT022357 confirms first, that it is
feasible to generate structurally different oral small molecule
drugs capable of maintaining utrophin transcription and second-
ly, these second-generation compounds have demonstrated sig-
nificant in vivo efficacy and better physicochemical properties
comparedwith SMTC1100. These observations support their con-
tinued development. The data presented in this publication fur-
ther endorses the therapeutic potential of utrophin modulation
as adiseasemodifying therapeutic strategy for all DMDpatients ir-
respective of the dystrophin mutation.
Materials and Methods
Ethics statement
All animal procedures were performed in accordance with UK
Home Office regulations which conform with the European
Community Directive published in 1986 (86/609/ EEC). The work
was performed under certificate of designation number 30/2306
and project license number 30/3104 following approval by the
University of Oxford Departments of Physiology, Anatomy &
Genetics and Experimental Psychology Joint Departmental Ethics
Review Committee.
Cell culture
The H2K-mdx utrnA-luc cells (41) were maintained in DMEM (In-
vitrogen) supplemented with 20% fetal bovine serum gold (PAA),
5% chicken embryo extract (SLI), 2 m -glutamine (Invitrogen),
1% penicillin–streptomycin (Invitrogen) and 1 mg/500 ml mouse
interferon-γ (Roche). Cells were maintained at 10% CO2 at 33°C.
In vitro assays
For luciferase assays, H2K-mdxutrnA-luc cellswere plated at 10 000
cells per well in a white solid tissue culture treated 96-well plate
(BD Falcon). These were incubated in 10% CO2 at 33°C for 24 h
prior to dosing. All compounds were supplied as a 10 m solution
in dimethyl sulfoxide (DMSO). Cells were treated with test com-
pounds dissolved at a final concentration of 1% DMSO and assays
performed in triplicate. Following 24 h incubation, luciferase levels
weremeasured using the Luciferase assay system (Promega E1501)
and plates read using a FLUOstar Optima plate reader (BMG
Labtech). The mean was calculated from biological triplicates.
Mice and drug treatment
Two-week-old male mdx (C57BL/10ScSn-Dmdmdx/J; Charles
River Laboratories, MA, USA) littermates were randomly split
and treated with SMT022357 (30 mg/kg) or vehicle only [phos-
phate buffered saline (PBS), 0.1%Tween-20, 5%DMSO] by daily in-
traperitoneal injection for 1 week and then daily oral gavage for a
further 4 weeks. At the end of drug treatment, mice were sacri-
ficed by CO2 asphyxiation in accordance with Schedule I of the
UK Animals (Scientific Procedures) Act 1986 and muscle and
blood samples taken.
Blood analyses
Blood was collected with non-heparinized haematocrit tubes
into serummicrotainer tubes and centrifuged for 2 min at 12 000
rpm. Serum was stored at −80°C prior to analysis using the CK
(NAC) reagent kit in conjunction with the AU 400 Clinical Chem-
istry analyser (Olympus UK Ltd).
Histological analyses
Muscle samples were frozen in liquid nitrogen-chilled isopen-
tane, and stored at −80°C. Transverse and longitudinal extensor
digitorum longus (EDL), tibialis anterior (TA), soleus (SOL), dia-
phragm (DIA) and heart cryosections (10 μm) were stained with
Haematoxylin and Eosin solution (H&E), Masson’s trichrome
(MT) and Alizarin red (AR). The Axioplan 2 Microscope System
(Carl Zeiss, Germany) was used to obtain the images. The propor-
tion of centrally nucleated fibres was determined by analysing
the H&E images. Areas of necrosis were quantified based on the
DMD_M.1.2.007 MDC1A_M.1.2.004 TREAT-NMD SOPS and per-
formed with the Fiji ImageJ 1.49i software (73) on the whole
EDL, SOL and DIA sections. Fibrosis of the whole DIA sections
was observed usingMasson’s trichrome staining to visualize con-
nective tissue and muscle fibres (Sigma kit HT15; SigmaAldrich)
and quantified using a previously published macro (74) with the
Fiji ImageJ 1.49i software.
Immunofluorescence
Frozen transverse and longitudinal muscle sections were blocked
in 10% foetal bovine serum/PBS for 20 min, incubatedwith primary
antibodies for 1 h at room temperature or overnight at 4°C, washed
in PBS and incubated with suitable Alexa Fluor secondary anti-
bodies for 1 h at room temperature. Sections were examined
under an Axioplan 2 Microscope System (Carl Zeiss, Germany).
The following antibodies and dilution were used: goat polyclonal
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anti-utrophin (1:500, URD40) (75), mouse monoclonal anti- β-dys-
troglycan (1:100, MANDAG2, CIND), rabbit monoclonal anti- α1-
CTFP/dystrobrevin (1:1000) (76), rabbit polyclonal anti desmin
(1:100, ab8592, abcam), rabbit polyconal anti-collagen type I (1:100,
600-401-103-0.5, Rockland), mouse anti-MYHC1 (1:200, B8-F8),
mouse anti-MYHC2A (1:200; SC-71); mouse IgM anti-MYHC2B
(1:100, BF-F3; all from German Collection of Microorganisms and
Cell Cultures) and polyclonal anti- α-Bungarotoxin AlexaFluo 488
conjugate antibody (1:500, B-13422, Life Technologies).
Protein analyses
Western blots were performed according to standard procedures.
Briefly, muscles were homogenized in Tris pH6.8 (75 m), SDS
(3.8%), Urea (4), glycerol (20%) supplemented with protease inhi-
bitors (1:100; Sigma-Aldrich). Thirty micrograms of total protein
were heat-denatured for 5 min at 100°C before loading onto Nu-
PAGE 3–8% TRIS Acetate Midi Gel (Novex, Life Technlogies) and
transferred to PVDF membranes (Millipore). Membranes were
blocked for 1 h with 10% skimmed milk in 0.1% PBS-Tween20
and then incubated with primary antibodies in 0.1% PBS-T for 1 h
at room temperature. Primary antibodies usedwere:mousemono-
clonal anti-utrophin [1:50, MANCHO3(84A), gift from G.E. Morris],
mouse monoclonal anti β-Dystroglycan (1:100, MANDAG2, CIND),
rabbit monoclonal anti-α1-CTFP/dystrobrevin (1/1000), mouse
monoclonal anti-Actin (1/1000, A2172, Sigma) and goat polyclonal
α-actinin Antibody (N-19) (1:30 000, sc-7453, Santa Cruz). HRP-
labelled secondary antibodies (Amersham) were incubated for 1 h
at room temperature. Immunoreactive bands were detected using
ECL Western Blot Detection Reagents (SuperSignal West Pico
Chemiluminescent Substrate, Thermo Scientific). The relative ex-
pression of the target proteins was estimated by densitometry
using Actin or Actinin N-19 as references on a Xograph Compact
X4 developer and quantified with the Fiji ImageJ 1.49i software.
RNA analyses
Cells were lysed in Buffer RLT and total RNAwas extracted using
the Qiagen RNeasy Kit (Qiagen) according to the manufacturer’s
instructions. 750 ng of total RNA was used to generate cDNA
using the QuantiTect Reverse Transcription kit (Qiagen). Real-
time PCRwas performed on the StepOne™Real-Time PCR system
(Applied Biosystems) with TaqMan® Fast Universal PCR Master
Mix (Life Technologies). Results were analysed according to the
Pfafflmethod (77), a derivative of the ΔΔCTmethod (78). Utrophin
(forward primer 5′-CGATGGACTCGCGTTCAAC-3′, reverse primer
5′ CCGGCACAAACCAGATC-3′) mRNA expression levels were nor-
malized to the ‘normalization factor’ obtained from the geNorm
software forMicrosoft Excel 2010which uses eukaryotic 18S rRNA
(Catalog number: 4310893E, Life Technologies) and B2m (Assay
number: Mm00437762_m1, Life Technologies) as reference
genes (stability value <1.5). PCR amplification efficiency was de-
termined by applying linear regression analysis to the exponen-
tial phase of the amplification curve of each PCR reaction using
the LinRegPCR software (79). No reverse transcriptase (non-RT),
no template control (NTC) reactions and non-contamination of
cDNAs by genomic DNA (ALBh) were used as negative controls
in each 40-cycle PCR run (Cq values NTC = undetermined, non-
RT = undetermined and ALBh >35).
Isolated muscle-function analysis
Peak force, specific force and force drop were measured from the
extensor digitorum longus muscle of the treated and control
mice. During dissection and experiments, muscles were bathed
in oxygenated (95% O2–5% CO2) Krebs–Hensley solution com-
posed of (mmol/l): NaCl, 118; NaHCO3, 24.8, KCl, 4.75; KH2PO4,
1.18; MgSO4, 1.18; CaCl2, 2.54; glucose, 10 (80). Contractile proper-
ties were measured as previously described (81). In brief, isolated
EDL were attached to a lever arm connected to a force transducer
(model 300B); and stimulator (model 701B); the equipment was
controlled using the signal interface (model 604A) and results
were recorded by the DMC software (version 4.1.4; Aurora Scien-
tific, Aurora, Ontario, Canada). Themusclewas stimulated by sin-
gle pulses of 0.2 ms at 30 V while the optimum length (Lo) was
determined. Optimum fibre length (Lf ) was calculated by multi-
plying Lo by the predetermined fibre length to muscle length
ratio of 0.44 (82). A force–frequency curve was generated and
the maximum isometric force calculated. Absolute force (Po) are
normalized to specific force (sPo; kN/m
2) using the equation
(muscle mass/Lf × 1.06 (the density of mammalian muscle). Per-
centage force drop were calculated by comparing maximum
force between the first (ECC1) and fifth eccentric (ECC5) contrac-
tions, expressed as a percentage of ECC1. The muscle was stimu-
lated into tetanus at the frequency required to generate the Po,
while in tetanic state the muscle was stretched at a rate of one
fibre length per second for 0.15 s, equating to a total stretch of
15% of fibre length. All data were digitized and analyzed using
the DMA software (version 3.2; Aurora Scientific).
Statistics
Results were analysed using Prism (GraphPad Software, Inc.) and
the Student’s t-test with a two-tailed distribution assuming
equal or unequal sample variance depending of the equality of
the variance (F-test). Data are presented as mean ± SEM (stand-
ard error of mean), with n indicating the number of independent
biological replicates used in each group for comparison. Differ-
ences were considered significant at (*) P < 0.05; (**) P < 0.01 and
(***) P < 0.001.
Compounds
SMT022357 was provided by Summit Therapeutics plc. Structure
and purity were confirmed by 1H NMR and LC-MS.
Supplementary Material
Supplementary Material is available at HMG online.
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